Literature DB >> 26165142

Mindin deficiency protects the liver against ischemia/reperfusion injury.

Peng Sun1, Peng Zhang2, Pi-Xiao Wang2, Li-Hua Zhu3, Yibao Du1, Song Tian2, Xueyong Zhu2, Hongliang Li4.   

Abstract

BACKGROUND & AIMS: Hepatic ischemia/reperfusion (I/R) injury often occurs during liver surgery and may cause liver failure. Our previous studies revealed that Mindin is involved in the pathogenesis of ischemic stroke. However, the function of Mindin in hepatic I/R injury remains unknown.
METHODS: Partial hepatic warm ischemia was induced in parallel in global Mindin knockout mice (Mindin KO), hepatocyte-specific Mindin knockdown mice, hepatocyte-specific Mindin transgenic mice (Mindin TG), myeloid cell-specific Mindin TG mice (LysM-Mindin TG), and their corresponding controls, followed by reperfusion. Hepatic histology, serum aminotransferase, inflammatory cytokines, and hepatocyte apoptosis and proliferation were examined to assess liver injury. The molecular mechanisms of Mindin function were explored in vivo and in vitro.
RESULTS: Mindin KO and hepatocyte-specific Mindin knockdown mice exhibited less liver damage than controls, with smaller necrotic areas and lower serum transaminase levels. Mindin deficiency significantly suppressed inflammatory cell infiltration, cytokine and chemokine production, and hepatocyte apoptosis, but increased hepatocyte proliferation following hepatic I/R injury. In contrast, the opposite pathological and biochemical changes were observed in hepatocyte-specific Mindin TG mice, whereas no significant changes in liver damage were found in LysM-Mindin TG mice compared to non-transgenic controls. Mechanistically, Akt signaling was activated in livers of Mindin KO mice but was suppressed in Mindin TG mice. Most importantly, Akt inhibitor treatment blocked the protective effect of Mindin deficiency on hepatic I/R injury.
CONCLUSIONS: Mindin is a novel modulator of hepatic I/R injury through regulating inflammatory responses, as well as hepatocyte apoptosis and proliferation via inactivation of the Akt signaling pathway.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Akt; Cell death; Hepatic ischemia/reperfusion; Inflammation; Mindin; Regeneration

Mesh:

Substances:

Year:  2015        PMID: 26165142     DOI: 10.1016/j.jhep.2015.06.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.

Authors:  Peng Zhang; Pi-Xiao Wang; Ling-Ping Zhao; Xin Zhang; Yan-Xiao Ji; Xiao-Jing Zhang; Chun Fang; Yue-Xin Lu; Xia Yang; Mao-Mao Gao; Yan Zhang; Song Tian; Xue-Yong Zhu; Jun Gong; Xin-Liang Ma; Feng Li; Zhihua Wang; Zan Huang; Zhi-Gang She; Hongliang Li
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

2.  An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury.

Authors:  Xiao-Jing Zhang; Xu Cheng; Zhen-Zhen Yan; Jing Fang; Xiaozhan Wang; Weijun Wang; Zhen-Yu Liu; Li-Jun Shen; Peng Zhang; Pi-Xiao Wang; Rufang Liao; Yan-Xiao Ji; Jun-Yong Wang; Song Tian; Xue-Yong Zhu; Yan Zhang; Rui-Feng Tian; Lin Wang; Xin-Liang Ma; Zan Huang; Zhi-Gang She; Hongliang Li
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

3.  Sufentanil Protects the Liver from Ischemia/Reperfusion-Induced Inflammation and Apoptosis by Inhibiting ATF4-Induced TP53BP2 Expression.

Authors:  Ling Zhou; Xinlu Yang; Shuhua Shu; Sheng Wang; Fenglin Guo; Ying Yin; Weide Zhou; Han Han; Xiaoqing Chai
Journal:  Inflammation       Date:  2021-03-10       Impact factor: 4.092

4.  Mindin deficiency alleviates renal fibrosis through inhibiting NF-κB and TGF-β/Smad pathways.

Authors:  Kang Yang; Wei Li; Tao Bai; Yusha Xiao; Weimin Yu; Pengcheng Luo; Fan Cheng
Journal:  J Cell Mol Med       Date:  2020-04-06       Impact factor: 5.310

5.  Tripartite Motif 8 Deficiency Relieves Hepatic Ischaemia/reperfusion Injury via TAK1-dependent Signalling Pathways.

Authors:  Qiu Tao; Wang Tianyu; Zhou Jiangqiao; Chen Zhongbao; Ma Xiaoxiong; Zhang Long; Zou Jilin
Journal:  Int J Biol Sci       Date:  2019-06-04       Impact factor: 6.580

6.  Six-Transmembrane Epithelial Antigen of the Prostate 3 Deficiency in Hepatocytes Protects the Liver Against Ischemia-Reperfusion Injury by Suppressing Transforming Growth Factor-β-Activated Kinase 1.

Authors:  Wen-Zhi Guo; Hong-Bo Fang; Sheng-Li Cao; San-Yang Chen; Jie Li; Ji-Hua Shi; Hong-Wei Tang; Yi Zhang; Pei-Hao Wen; Jia-Kai Zhang; Zhi-Hui Wang; Xiao-Yi Shi; Chun Pang; Han Yang; Bo-Wen Hu; Shui-Jun Zhang
Journal:  Hepatology       Date:  2019-10-11       Impact factor: 17.425

7.  Hesperidin ameliorates liver ischemia/reperfusion injury via activation of the Akt pathway.

Authors:  Shilai Li; Quanlin Qin; Daqing Luo; Wenhui Pan; Yuqing Wei; Yansong Xu; Jijin Zhu; Liming Shang
Journal:  Mol Med Rep       Date:  2020-10-06       Impact factor: 2.952

8.  Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice.

Authors:  Xiao-Shen Cheng; Ya-Ni Huo; Yan-Yun Fan; Chuan-Xing Xiao; Xiao-Mei Ouyang; Lai-Ying Liang; Ying Lin; Jian-Feng Wu; Jian-Lin Ren; Bayasi Guleng
Journal:  J Cell Mol Med       Date:  2020-07-02       Impact factor: 5.310

9.  Maresin 1 protects the liver against ischemia/reperfusion injury via the ALXR/Akt signaling pathway.

Authors:  Da Tang; Guang Fu; Wenbo Li; Ping Sun; Patricia A Loughran; Meihong Deng; Melanie J Scott; Timothy R Billiar
Journal:  Mol Med       Date:  2021-02-25       Impact factor: 6.354

10.  Neutralization of CD95 ligand protects the liver against ischemia-reperfusion injury and prevents acute liver failure.

Authors:  Mohammed Al-Saeedi; Niels Steinebrunner; Hassan Kudsi; Niels Halama; Carolin Mogler; Markus W Büchler; Peter H Krammer; Peter Schemmer; Martina Müller
Journal:  Cell Death Dis       Date:  2018-01-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.